Preclinical assessment of infant formula

Bo Lönnerdal

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Infant formulas are the sole or predominant source of nutrition for many infants and are fed during a sensitive period of development and may therefore have short- and long-term consequences for infant health. Preclinical safety assessment therefore needs to include both short-term and long-term studies in animals. It is recommended that procedures are instituted by which experts may serve as independent scientists for companies developing novel products, without having their integrity compromised, and later serve the legislative institutions. A two-level assessment approach to determine the potential toxicity of a novel ingredient, its metabolites, and their effects in the matrix on developing organ systems has been suggested by IOM. This appears reasonable, as novel ingredients can be of different levels of concern. The use of modern methods in genomics and proteomics should be considered in these evaluation processes as well as novel methods to evaluate outcomes, including metabolomics and molecular techniques to assess the microbiome.

Original languageEnglish (US)
Pages (from-to)196-199
Number of pages4
JournalAnnals of Nutrition and Metabolism
Volume60
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Infant Formula
Metabolomics
Needs Assessment
Microbiota
Genomics
Proteomics
Safety

Keywords

  • Infant formula
  • Novel ingredients
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Preclinical assessment of infant formula. / Lönnerdal, Bo.

In: Annals of Nutrition and Metabolism, Vol. 60, No. 3, 06.2012, p. 196-199.

Research output: Contribution to journalArticle

Lönnerdal, Bo. / Preclinical assessment of infant formula. In: Annals of Nutrition and Metabolism. 2012 ; Vol. 60, No. 3. pp. 196-199.
@article{a80b0cbab229499b8819eaa494e01023,
title = "Preclinical assessment of infant formula",
abstract = "Infant formulas are the sole or predominant source of nutrition for many infants and are fed during a sensitive period of development and may therefore have short- and long-term consequences for infant health. Preclinical safety assessment therefore needs to include both short-term and long-term studies in animals. It is recommended that procedures are instituted by which experts may serve as independent scientists for companies developing novel products, without having their integrity compromised, and later serve the legislative institutions. A two-level assessment approach to determine the potential toxicity of a novel ingredient, its metabolites, and their effects in the matrix on developing organ systems has been suggested by IOM. This appears reasonable, as novel ingredients can be of different levels of concern. The use of modern methods in genomics and proteomics should be considered in these evaluation processes as well as novel methods to evaluate outcomes, including metabolomics and molecular techniques to assess the microbiome.",
keywords = "Infant formula, Novel ingredients, Safety, Toxicity",
author = "Bo L{\"o}nnerdal",
year = "2012",
month = "6",
doi = "10.1159/000338209",
language = "English (US)",
volume = "60",
pages = "196--199",
journal = "Annals of Nutrition and Metabolism",
issn = "0250-6807",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Preclinical assessment of infant formula

AU - Lönnerdal, Bo

PY - 2012/6

Y1 - 2012/6

N2 - Infant formulas are the sole or predominant source of nutrition for many infants and are fed during a sensitive period of development and may therefore have short- and long-term consequences for infant health. Preclinical safety assessment therefore needs to include both short-term and long-term studies in animals. It is recommended that procedures are instituted by which experts may serve as independent scientists for companies developing novel products, without having their integrity compromised, and later serve the legislative institutions. A two-level assessment approach to determine the potential toxicity of a novel ingredient, its metabolites, and their effects in the matrix on developing organ systems has been suggested by IOM. This appears reasonable, as novel ingredients can be of different levels of concern. The use of modern methods in genomics and proteomics should be considered in these evaluation processes as well as novel methods to evaluate outcomes, including metabolomics and molecular techniques to assess the microbiome.

AB - Infant formulas are the sole or predominant source of nutrition for many infants and are fed during a sensitive period of development and may therefore have short- and long-term consequences for infant health. Preclinical safety assessment therefore needs to include both short-term and long-term studies in animals. It is recommended that procedures are instituted by which experts may serve as independent scientists for companies developing novel products, without having their integrity compromised, and later serve the legislative institutions. A two-level assessment approach to determine the potential toxicity of a novel ingredient, its metabolites, and their effects in the matrix on developing organ systems has been suggested by IOM. This appears reasonable, as novel ingredients can be of different levels of concern. The use of modern methods in genomics and proteomics should be considered in these evaluation processes as well as novel methods to evaluate outcomes, including metabolomics and molecular techniques to assess the microbiome.

KW - Infant formula

KW - Novel ingredients

KW - Safety

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84862494829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862494829&partnerID=8YFLogxK

U2 - 10.1159/000338209

DO - 10.1159/000338209

M3 - Article

VL - 60

SP - 196

EP - 199

JO - Annals of Nutrition and Metabolism

JF - Annals of Nutrition and Metabolism

SN - 0250-6807

IS - 3

ER -